Zevra Therapeutics (ZVRA) Moves 9.1% Higher: Will This Strength Last? [Yahoo! Finance]
Xeris Biopharma Holdings, Inc. (XERS)
Last xeris biopharma holdings, inc. earnings: 3/11 06:00 am
Check Earnings Report
Company Research
Source: Yahoo! Finance
The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 7.2% gain over the past four weeks. Last week, Zevra won the FDA approval for arimoclomol as an orally delivered treatment for Niemann-Pick disease type C (NPC). The drug will be marketed under the brand name, Miplyffa, in the United States for this indication. This marked a milestone achievement for the company as Miplyffa, in combination with miglustat, becomes the first NPC drug approved by the FDA to treat neurological manifestations of NPC in adult and pediatric patients, aged 2 years and older. Zevra also received a rare pediatric disease priority review voucher from the FDA, following the approval. The rise in Zevra's stock price is likely due to this announcement. This specialty pharmaceutical company is expected to post quarterly loss of $0.43 per share in its upcoming report, which represents a year-over-year change of -7.5%. Revenues are expecte
Show less
Read more
Impact Snapshot
Event Time:
XERS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
XERS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
XERS alerts
High impacting Xeris Biopharma Holdings, Inc. news events
Weekly update
A roundup of the hottest topics
XERS
News
- Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) most popular amongst individual investors who own 53% of the shares, institutions hold 43% [Yahoo! Finance]Yahoo! Finance
- Xeris to Participate in Upcoming Investor ConferencesBusiness Wire
- Xeris Biopharma Holdings, Inc. (NASDAQ: XERS) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $6.00 price target on the stock.MarketBeat
- Xeris Biopharma: Q2 Earnings Snapshot [Yahoo! Finance]Yahoo! Finance
- Xeris Biopharma Reports Second Quarter 2024 Financial ResultsBusiness Wire
XERS
Earnings
- 8/8/24 - Beat
XERS
Analyst Actions
- 8/15/24 - HC Wainwright
XERS
Sec Filings
- 8/13/24 - Form 4
- 8/12/24 - Form 4
- 8/9/24 - Form 4
- XERS's page on the SEC website